These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. Aguilar LK; Guzik BW; Aguilar-Cordova E J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529 [TBL] [Abstract][Full Text] [Related]
25. Peptide-based vaccines for cancer therapy. Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658 [TBL] [Abstract][Full Text] [Related]
26. Processing and presentation of tumor antigens and vaccination strategies. van der Bruggen P; Van den Eynde BJ Curr Opin Immunol; 2006 Feb; 18(1):98-104. PubMed ID: 16343880 [TBL] [Abstract][Full Text] [Related]
28. Promises and limitations of murine models in the development of anticancer T-cell vaccines. Lévy F; Colombetti S Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777 [TBL] [Abstract][Full Text] [Related]
29. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391 [TBL] [Abstract][Full Text] [Related]
30. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Moschella F; Proietti E; Capone I; Belardelli F Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466 [TBL] [Abstract][Full Text] [Related]
31. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Saxena M; Bhardwaj N Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279 [TBL] [Abstract][Full Text] [Related]
32. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens. Burdin N; Moingeon P Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697 [TBL] [Abstract][Full Text] [Related]
33. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880 [TBL] [Abstract][Full Text] [Related]
34. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452 [TBL] [Abstract][Full Text] [Related]
35. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273 [TBL] [Abstract][Full Text] [Related]